drugset / Trial / NCT05248841

A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

NCT05248841

RandomizedCrossoverDouble-blindTreatment

Summary

This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.

Timeline

Start
2022-03-08
Primary completion
2022-08-31
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC-Glargine Unknown 0.5 iu/kg Subcutaneous
Comparator insulin glargine Protein / enzyme biologic 0.5 iu/kg Subcutaneous